You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Salivary Gland Neoplasms

Showing 1 - 25 of 4,550
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Immune Biomarker Study for Salivary Gland Carcinoma

Not yet recruiting
  • Salivary Gland Tumor
  • Benign Salivary Gland Tumor
  • Sampling
  • Erlangen, Bavaria, Germany
  • +1 more
Sep 21, 2023

GENE EXPRESSION PROFILING IN A VALIDATION COHORT OF LOCALLY

Not yet recruiting
  • Salivary Gland Cancer
  • Observation
  • (no location specified)
Oct 13, 2023

Salivary Gland Tumor, Diagnosis Trial in Thessaloníki (Fine Needle Aspiration, Histologic Examination)

Completed
  • Salivary Gland Tumor
  • Diagnosis
  • Fine Needle Aspiration
  • Histologic Examination
  • Thessaloníki, Greece
    Aristotle University
Sep 11, 2023

Gland, Salivary Gland Cancers Trial in Houston (Sacituzumab Govitecan)

Not yet recruiting
  • Gland
  • Salivary Gland Cancers
  • Sacituzumab Govitecan
  • Houston, Texas
    M D Anderson Cancer Center
May 22, 2023

Advanced Salivary Gland Carcinoma Trial in Shanghai (SHR-A1811, SHR 3680 + leuprolide, SHR-A1921)

Not yet recruiting
  • Advanced Salivary Gland Carcinoma
  • Shanghai, China
    Dongmei Ji
Jun 21, 2023

PSMA-PET Imaging of Salivary Gland Tumours and Other Rare

Recruiting
  • Salivary Gland Tumor
  • Rare Malignant Neoplasm
  • 68-Ga PSMA PET scan
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 11, 2022

Salivary Gland Cancer, Salivary Gland Tumors Trial in Novi Sad (Surgical intervention with or without postoperative adjuvant

Completed
  • Salivary Gland Cancer
  • Salivary Gland Neoplasms
  • Surgical intervention with or without postoperative adjuvant therapy
  • Novi Sad, Serbia
    Clinic for maxillofacial surgery Clinical center of Vojvodina
May 22, 2022

Salivary Gland Cancer Trial (vedicitumomab (Edisil, RC48), vedicitumomab in combination with pyrrolizidine, RC48 in combination

Not yet recruiting
  • Salivary Gland Cancer
  • vedicitumomab (Edisil, RC48）
  • +3 more
  • (no location specified)
Jun 9, 2023

Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma Trial in Nijmegen (Lutetium-177-PSMA-I&T)

Recruiting
  • Salivary Gland Cancer
  • +2 more
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Oct 27, 2022

High-grade Salivary Gland Carcinoma Trial in Seoul (nivolumab, docetaxel, cisplatin Group)

Recruiting
  • High-grade Salivary Gland Carcinoma
  • nivolumab, docetaxel, cisplatin Group
  • Seoul, Korea, Republic of
    Department of Medicine, Samsung Medical Center, Sungkyunkwan Uni
Feb 3, 2023

Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,

Recruiting
  • Salivary Gland Cancer
  • HER2 Gene Mutation
  • Ado-trastuzumab (T) emtansine (T-DM1)
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 2, 2023

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in

Recruiting
  • Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2023

Salivary Gland Tumor Trial in Philadelphia (MRI)

Recruiting
  • Salivary Gland Tumor
  • MRI
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Jun 19, 2022

Salivary Gland Tumors Trial in Beijing (RC48-ADC)

Recruiting
  • Salivary Gland Tumors
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 28, 2022

Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial

Not yet recruiting
  • Locally Advanced Salivary Gland Carcinoma
  • +3 more
  • Biopsy
  • +3 more
  • (no location specified)
Jan 10, 2023

Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer Trial in Boston (9-ING-41, Carboplatin)

Withdrawn
  • Salivary Gland Carcinoma
  • +3 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Feb 5, 2022

Salivary Gland Cancer Trial in Japan (Darolutamide, Goserelin)

Recruiting
  • Salivary Gland Cancer
  • Nagoya, Aichi, Japan
  • +11 more
Jan 21, 2023

Salivary Gland Cancer, Salivary Duct Carcinoma Trial in Nijmegen (68Ga-PSMA-PET/CT, 18FDG-PET/CT)

Recruiting
  • Salivary Gland Cancer
  • Salivary Duct Carcinoma
  • 68Ga-PSMA-PET/CT
  • 18FDG-PET/CT
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Aug 15, 2022

Thyroid Cancer, Salivary Gland Cancer Trial in Chicago (Pembrolizumab, Docetaxel)

Recruiting
  • Thyroid Cancer
  • Salivary Gland Cancer
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Apr 13, 2022

Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)

Recruiting
  • Salivary Gland Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Feb 18, 2022

Salivary Gland Cancer Trial in Cincinnati (Amivantamab)

Recruiting
  • Salivary Gland Cancer
  • Cincinnati, Ohio
    University of Cincinnati Medical Center
Aug 5, 2022

Salivary Gland Carcinoma Trial in United States (Goserelin Acetate, Pembrolizumab)

Recruiting
  • Salivary Gland Carcinoma
  • Chicago, Illinois
  • +6 more
Sep 22, 2022

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

Salivary Gland Tumors Trial in Shanghai (Pyrotinib, Bicalutamide, Leuprorelin)

Recruiting
  • Salivary Gland Neoplasms
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Ton
Oct 8, 2021

Adenoid Cystic Carcinoma, Salivary Gland Cancer Trial in United States (Lenvatinib, Pembrolizumab)

Recruiting
  • Adenoid Cystic Carcinoma
  • Salivary Gland Cancer
  • Miami, Florida
  • +7 more
Oct 26, 2022